Product Name :
Rociletinib hydrobromide
Description:
Rociletinib hydrobromide (CO-1686 hydrobromide) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.
CAS:
1446700-26-0
Molecular Weight:
636.46
Formula:
C27H29BrF3N7O3
Chemical Name:
N-3-[(2-[4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl]amino-5-(trifluoromethyl)pyrimidin-4-yl)amino]phenylprop-2-enamide; bromohydrogen
Smiles :
Br.CC(=O)N1CCN(CC1)C1C=C(OC)C(=CC=1)NC1N=C(NC2=CC(=CC=C2)NC(=O)C=C)C(=CN=1)C(F)(F)F
InChiKey:
IPKRDUJIGYXXNT-UHFFFAOYSA-N
InChi :
InChI=1S/C27H28F3N7O3.BrH/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38;/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35);1H
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Rociletinib hydrobromide (CO-1686 hydrobromide) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.|Product information|CAS Number: 1446700-26-0|Molecular Weight: 636.46|Formula: C27H29BrF3N7O3|Chemical Name: N-3-[(2-[4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl]amino-5-(trifluoromethyl)pyrimidin-4-yl)amino]phenylprop-2-enamide; bromohydrogen|Smiles: Br.CC(=O)N1CCN(CC1)C1C=C(OC)C(=CC=1)NC1N=C(NC2=CC(=CC=C2)NC(=O)C=C)C(=CN=1)C(F)(F)F|InChiKey: IPKRDUJIGYXXNT-UHFFFAOYSA-N|InChi: InChI=1S/C27H28F3N7O3.Mecillinam In stock BrH/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38;/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35);1H|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : ≥ 59 mg/mL (92.Trimetrexate DNA/RNA Synthesis 70 mM).PMID:33257139 H2O : Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Rociletinib (0.1 μM) inhibits EGFR potently and irreversibly, and inhibits more than 50% of 23 targets. Rociletinib potently and selectively inhibits growth of NSCLC cells expressing mutant EGFR and induces apoptosis. Rociletinib resistant NSCLC cell lines are sensitive to AKT inhibition.|In Vivo:|Rociletinib (100 mg/kg/day, p.o.) demonstrates anti-tumor activity in NSCLC EGFR mutant xenograft models. Rociletinib (50 mg/kg bid, p.o.) demonstrates anti-tumor activity in human EGFR-L858R and EGFR-L858R-T790M expressing transgenic mice.|Products are for research use only. Not for human use.|
